The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Safety and tolerability of caspofungin acetate in the treatment of fungal infections
Abstract
Caspofungin acetate is the first member of the novel echinocandin class of antifungal drugs to be marketed in the United States. It has recently been approved for use in patients with invasive aspergillosis who are refractory to or intolerant of conventional therapy. Accordingly, its safety profile is particularly important to review. The safety and tolerability of caspofungin have been examined in 623 persons, including 295 patients who received >/= 50 mg/day for at least one week in clinical studies. In the 263 patients, given caspofungin in randomized double-blind active-control trials to date, there have been no serious clinical or laboratory drug-related adverse events; caspofungin was discontinued in only 2% of these patients because of drug-related adverse experiences. Caspofungin may have potentially important drug interactions with cyclosporine and tacrolimus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Caspofungin has been shown to be as effective as both amphotericin B deoxycholate and fluconazole when used as therapy for oropharyngeal and esophageal candidiasis [57][58][59][60].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [57]
Citations
Cites
Discovery of Novel Antifungal (1,3)-β- d -Glucan Synthase Inhibitors
Onishi, J. C., Meinz, M., Thompson, J. R., Curotto, J. E., Dreikorn, S., Rosenbach, M. J., Douglas, C. M., Abruzzo, G. K., Flattery, A. M., Kong, L., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.368-377.2000 · Cited by 329
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Current and future antifungal therapy: new targets for antifungal agents
Andriole, V. T. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.151 · Cited by 191
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
Hajdu, R., Thompson, R. K., Sundelof, J. G., PELAK, B. A., Bouffard, F. A., Dropinski, J. F., & Kropp, H. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2339 · Cited by 165
Metabolites of Caspofungin Acetate, a Potent Antifungal Agent, in Human Plasma and Urine
Balani, S. K., Xu, X., Arison, B. H., da Silva, M. V. M., Gries, A., Deluna, F. A., Cui, D., Kari, P. H., Ly, T., Hop, C. E. C. A., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15072-6 · Cited by 104
Research works printed but not linked: 6
- SableCA VillaneuvaA ArathoonE et al.A randomized double‐blind multicenter trial of MK‐0991 (L‐743872) versus amphotericin B (AMB) in the treatment ofCandidaesophagitis in adults.Presented at the 37th Interscience Conference on Antimicrobial Agents Chemotherapy.Toronto Ontario Canada October 1997: LB‐33.
- Stone JS, 1998, Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Xu X, 1998, Disposition of MK‐0991, a potent antifungal agent, in rats with acute renal failure, Pharm Sci, 1, 463
- Stone JA, 2000, Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
- Stone JA, 2000, Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
- Stone J, 2001, Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy;
Cited by
Sorted by citations
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationInfection in Organ Transplantation
Fishman, J. A. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14208 · Cited by 858
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease
Bulpa, P., Dive, A., & Sibille, Y. (2007) · European Respiratory Journal · doi:10.1183/09031936.00062206 · Cited by 470
Metadata
- Authors
- Sable, C. A., Nguyen, B. T., Chodakewitz, J. A., & DiNubile, M. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Transplant Infectious Disease
- Publisher
- Wiley
- Published
- 2002-03
- Volume
- 4
- Issue
- 1
- Pages
- 25-30
- ISSN
- 1398-2273 (ISSN-L)
- 1399-3062
- OpenAlex
- W2041457471
- Cited by
- 148
- References
- 5
- Citations by year
- 2025: 4 · 2024: 2 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 7 · 2013: 4 · 2012: 7
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplant Infectious Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- caspofungin acetate, echinocandins, antifungal agents, invasive aspergillosis, drug safety, tolerability, adverse drug reactions, refractory fungal infection
- MeSH terms
- Caspofungin, Anti-Bacterial Agents, Antifungal Agents, Aspergillosis, Candidiasis, Double-Blind Method, Drug Tolerance, Fever, Headache, Humans, Mycoses, Peptides, Peptides, Cyclic, Phlebitis, Retrospective Studies, Randomized Controlled Trials as Topic, Immunocompromised Host, Drug Approval, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
